| |
Financial Year 2008 - 2009
Quarter I
(June 2008)
Financial Year 2007 - 2008
Quarter IV
(March 2008)
Quarter III
(December 2007)
Quarter II
(September 2007)
Quarter I
(June 2007)
Financial Year 2006 - 2007
Quarter IV
(March 2007)
Quarter III
(December 2006)
Quarter II
(September 2006)
Quarter I
(June 2006)
Financial Year 2005 - 2006
Quarter IV
(March 2006)
Quarter III
(December 2005)
Quarter II
(September 2005)
Quarter I
(June 2005)
Financial Year 2004 - 2005
Quarter IV
(March 2005)
Quarter III
(December 2004)
Quarter II
(September 2004)
Quarter I
(June 2004)
Financial Year 2003 - 2004
Quarter IV
(March 2004)
Quarter III
(December 2003)
Quarter II
(September 2003)
Quarter I
(June 2003)
Financial Year 2002 - 2003
Quarter IV
(March 2003)
Quarter III
(December 2002)
Quarter II
(September 2002)
Quarter I
(June 2002)
|
MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE PERIOD ENDED
31st DECEMBER 2007
| (Rs.in Million ) |
| Sl. No |
Particulars |
Quarter ended 31st December |
9 months ended 31st December |
Year ended
31st March 2007
(Audited) |
| 2007 (Un Audited) |
2006 (Un Audited) |
2007 (Un Audited) |
2006 (Audited) |
01.
02.
03.
04.
05.
06.
07.
08.
09.
10.
11.
12.
13.
14.
15.
16.
|
Net Sales/Income from Operations
- Sales (net)
- Other Income for Operation
- Income from Potential patent infringment suit
total
Other Income
Total Income(1+2)
Expenditure
a) (Increase) / Decrease in Stock trade and
work in progress
b) Materials Consumed
c) Purchase of traded goods
d) Employee.cost
e)Depreciation
& Amortization
f)Other Expenditure
Total Expenditure
Profit before R&D& Interest(3-4)
Research and Development Expenditure
Interest
Profit from Ordinary Activities before Tax(5-6-7)
Tax expense(net)
Profit /(Loss) after Tax before Minority Interest and share in
Less : Minority Interest
Less : Share of loss in associate
Net Profit/ (Loss) (11-12-13)
Equity Capital
Reserves excluding revaluation reserves
E.P.S (Not annualised)
- Basic
- Diluted
|
4,449.36
18.39
67.65
4,535.40
58.86
4,594.26
(416.76)
1,883.01
714.64
531.52
181.16
820.39
3,713.96
880.30
341.95
263.84
274.51
130.11
144.40
7.02
2.90
154.32
309.18
-
1.00
1.00
|
3,952.52
13.83
67.65
4,034.00
113.67
4,147.67
100.24
975.30
1,124.22
447.77
148.24
820.89
3,616.66
531.01
262.86
203.97
64.18
67.37
(3.19)
(3.55)
(2.00)
(8.74)
307.96
-
(0.06)
(0.06)
|
12,683.62
50.29
202.22
12,936.13
197.32
13,133.45
(384.02)
4,712.78
2,256.04
1,398.02
479.79
2,332.22
10,794.83
2,338.62
981.49
706.93
650.20
362.89
287.31
39.17
(2.57)
323.91
309.18
-
2.10
2.09
|
12,105.90
43.20
202.22
12,351.32
217.89
12,569.21
(162.63)
3,675.08
3,283.52
1,375.94
413.84
2,168.28
10,754.03
1,815.18
666.14
555.42
593.62
86.37
507.25
(13.70)
(5.68)
487.87
307.96
-
3.17
3.10
|
16,480.27
44.16
268.39
16,792.82
231.79
17,024.61
(250.84)
5,332.35
3,898.76
1,773.35
540.70
2,997.12
14,291.44
2,733.17
1,007.56
704.19
1,021.42
264.89
756.53
6.57
0.00
763.10
308.24
-
4.96
4.93
|
Segment Information
Segment Revenue:
-Pharmaceuticals
-Medical Supplies
Less: Inter segment Revenue
Net Segment Revenue
Segment Results :
Profit before tax and interest from each segment
-Pharmaceuticals
-Medical Supplies
Total
Less: Interest
Other unallocable
Income/(Expenditure)
Total Profit before tax
Capital Employed :
-Pharmaceuticals
-Medical Supplies
-Unallowable
Total Capital Employed :
|
4,040.90
408.46
-
4,449.36
515.05
23.30
538.35
(263.84)
-
274.51
14,206.71
432.65
11,957.03
26,596.39
|
3,369.16
583.36
-
3,952.52
188.12
80.03
268.15
(203.97)
-
64.18
13,162.23
299.24
12,011.86
25,473.33
|
11,542.02
1,141.60
-
12,683.62
1,306.15
50.98
1,357.13
(706.93)
-
650.20
14,206.71
432.65
11,957.03
26,596.39
|
10,381.86
1,724.04
-
12,105.90
1,028.80
120.24
1,149.04
(555.42)
-
593.62
13,162.23
299.24
12,011.86
25,473.33
|
14,283.02
2,197.25
-
16,480.27
1,627.41
98.20
1,725.61
(704.19)
-
1,021.42
15,403.30
188.21
11,920.21
27,511.72
|
|
| Notes : |
The above results were subjected to a limited review by the Auditors, reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 25th January 2008.
The figures for the previous year / period have been rearranged wherever necessary to conform to current quarter's presentation. - Matrix Laboratories Limited, through its wholly owned subsidiary, had executed definitive agreements with the erstwhile promoter of MChem group of companies, China to acquire his residual shareholding in MChem group of companies. On receipt of the requisite approvals, the transaction for purchase of the residual stake has since been completed. With the purchase of the residual stake, the effective holding of the Company in MChem group of companies, through its wholly owned subsidiary, stands at 97%.
|
| |
For and on behalf of the Board
|
Place : Secunderabad
Date : 25th January 2008 |
N. Prasad
Vice Chairman
|
|
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED
31st December 2007
| (Rs.in Million ) |
| Sl. No |
Particulars |
Quarter ended 31st December |
9 months ended 31st December |
Year ended
31st March 2007
(Audited) |
| 2007 (Un Audited) |
2006 (Un Audited) |
2007 (Un Audited) |
2006 (Un Audited) |
01.
02.
03.
04.
05.
06.
07.
08.
09.
10.
11.
12.
13.
14.
| Net Sales/Income from Operation
-Exports
-Domestic
-Other Income from Operations
-Income from Potential patent infringement suit
Total
Other Income
Total Income(1+2)
Expenditure
a) (Increase) / Decrease in Stock in trade and work in progress
b) Materials Consumed
c) Purchase of traded goods
d)Employee cost
e)Depreciation & Amortization
f) Other Expenditure
Total Expenditure
Profit before R&D,Interest(3-4)
Research and Development Expenditure
Interest
Profit from Ordinary Activities before tax(5-6-7)
Tax expenses(net)
Net Profit for the period(8-9)
Paid-up equity share Capital(Face value - Rs.2/- each)
Reserves excluding revaluation reserves
Earning Per Share(E.P.S)(Not annualised)
- Basic
- Diluted
Public Shareholding
-Number of shares
-Percentage of Shareholding
|
1710.93
941.82
36.79
67.65
2,757.19
38.31
2,795.50
(278.37)
1,574.72
0.44
187.69
74.03
421.85
1,980.36
815.14
289.57
79.74
445.83
102.34
343.49
309.18
-
2.23
2.23
36,876,696
23.85%
|
1,196.64
543.66
27.67
67.65
1,835.62
38.38
1,874.00
(304.37)
1,174.24
91.11
151.68
64.31
364.81
1,541.78
332.22
214.09
42.80
75.33
8.78
66.55
307.96
-
0.43
0.42
69,100,420
44.88%
|
4,235.68
2,498.64
100.58
202.22
7,037.12
154.42
7,191.54
(410.56)
3,791.51
1.73
532.38
219.93
1,151.11
5,286.10
1,905.44
740.74
183.33
981.37
243.56
737.81
309.18
-
4.78
4.76
36,876,696
23.85%
|
3,189.28
1,909.65
86.41
202.22
5,387.56
128.88
5,516.44
25.42
2,732.11
95.99
438.53
185.13
914.12
4,391.30
1,125.14
517.84
109.46
497.84
45.48
452.36
307.96
-
2.94
2.87
69,100,420
44.88%
|
5051.77
2440.44
88.33
268.39
7,848.93
162.08
8,011.01
(28.22)
3,789.51
99.03
598.38
250.71
1,271.52
5,980.93
2,030.08
800.92
154.01
1,075.15
79.02
996.13
308.24
9,388.77
6.48
6.43
36,405,635
23.62%
|
|
| Notes : |
- The above results were subjected to a limited review by the Auditors, reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 25th January 2008.
- The figures for the previous year / period have been rearranged wherever necessary to conform to current quarter's presentation
- The activities of the Company relate to only one business segment i.e. Pharmaceuticals.
- During the Quarter 93,785 Equity Shares of Rs.2 each at a premium of Rs.141.136 were allotted, on exercise of stock options under the Employees Stock Option Scheme.
- Matrix Laboratories Limited, through its wholly owned subsidiary, had executed definitive agreements with the erstwhile promoter of MChem group of companies, China to acquire his residual shareholding in MChem group of companies. On receipt of the requisite approvals, the transaction for purchase of the residual stake has since been completed. With the purchase of the residual stake, the effective holding of the Company in MChem group of companies, through its wholly owned subsidiary, stands at 97%.
- Summary of Investor Complaints
Opening : Nil , Received during the quarter : Nil , Resolved : Nil , Closing : Nil
- Provision for tax includes Current tax Rs.50.48 Millions (Quarter year ended 31st December 2006 Rs.2 Millions), Deferred tax Rs.91.64 Millions (Quarter ended 31st December 2006 Rs.6.78 Millions) and Fringe benefit tax Rs.5.5 Million (Quarter ended 31st December 2006 Rs.2 Millions) and is net of MAT credit available of Rs.45.28 Millions (Quarter ended 31st December 2006 Rs.2 Millions).
|
| |
For and on behalf of the Board
|
Place : Secunderabad
Date : 25th January 2008 |
N. Prasad
Vice Chairman
|
|
|
